Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study | Zendy

Wulf Sienel | Zendy; Claudia Varwerk | Zendy; A. Linder | Zendy; D. Kaiser | Zendy; M. Teschner | Zendy; M Delire | Zendy; Georgios Stamatis | Zendy; Bernward Passlick | Zendy

Open Access

Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study

Author(s) -

Wulf Sienel,

Claudia Varwerk,

A. Linder,

D. Kaiser,

M. Teschner,

M Delire,

Georgios Stamatis,

Bernward Passlick

Publication year - 2003

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2003.09.015

Subject(s) - lung cancer , stage (stratigraphy) , immunotherapy , medicine , cancer , antigen , oncology , melanoma , cell , cancer immunotherapy , cancer research , pathology , immunology , biology , paleontology , genetics

Adjuvant immunotherapy is an innovative therapeutic option that might potentially improve outcome of early-stage non-small cell lung cancer. Melanoma associated antigen (MAGE)-A3 is a promising target for immunotherapy because it is exclusively presented on the cell surface of cancer cells and might be associated with an aggressive cancer phenotype. The present study was performed to determine the rate of MAGE-A3 expression in early-stage non-small cell lung cancer (NSCLC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research